Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Rapt Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
RAPT
Nasdaq
8731
https://rapt.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Rapt Therapeutics Inc
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- Apr 9th, 2024 4:00 pm
3 Biotech Stocks to Dump Before They Go to Zero
- Apr 9th, 2024 10:31 am
What Makes RAPT Therapeutics (RAPT) an Investment Choice?
- Mar 22nd, 2024 9:39 am
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
- Mar 7th, 2024 1:36 pm
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 7th, 2024 1:00 pm
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
- Mar 5th, 2024 9:30 pm
Insider Buyers Lose Additional US$63k As RAPT Therapeutics Dips To US$236m
- Feb 21st, 2024 10:32 am
Rapt Therapeutics Crashes 74% After Unexpected Liver Failure Sidelines Two Tests
- Feb 20th, 2024 9:03 pm
RAPT Therapeutics Stock Is Down 63%. FDA Halts 2 Studies After Liver Failure.
- Feb 20th, 2024 4:22 pm
UPDATE 1-FDA puts on hold two Rapt Therapeutics mid-stage drug trials
- Feb 20th, 2024 12:58 pm
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
- Feb 20th, 2024 12:30 pm
FDA puts hold on Rapt trials of drug for eczema, asthma
- Feb 20th, 2024 12:17 pm
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
- Feb 13th, 2024 1:00 pm
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Jan 31st, 2024 1:00 pm
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2024 1:00 pm
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
- Nov 27th, 2023 1:00 pm
RAPT Therapeutics Inc Reports Increased R&D Expenses Amid Progress in Clinical Trials
- Nov 15th, 2023 12:41 am
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
- Nov 13th, 2023 1:00 pm
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
- Nov 3rd, 2023 4:00 pm
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
- Nov 1st, 2023 8:05 pm
Scroll